Skip to main navigation
Rhythm Pharmaceuticals, Inc. Logo
  • Careers
  • Investors & Media
  • International
  • Search
  • Science
    • MC4R Pathway
    • Clinical Focus
    • Research & Development
  • Clinical Trials
  • Patients
    • Disease Focus
  • Product
  • About
    • Our People
    • Leadership
  • Science
    • MC4R Pathway
    • Clinical Focus
    • Research & Development
  • Clinical Trials
  • Patients
    • Disease Focus
  • Product
  • About
    • Our People
    • Leadership
  • Careers
  • Investors & Media
  • International
  • Search
  • Overview
  • Events & Presentations
  • Stock
  • Corporate Governance
  • Financials
    • SEC Filings
    • Quarterly Results
    • Annual Reports
  • News
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contact Us

News

September 19, 2016
FierceBiotech Names Rhythm as a “Fierce 15” Biotechnology Company of 2016
July 27, 2016
Rhythm Announces “The Genetic Obesity Project” to Expand Understanding of Rare Genetic Disorders of Obesity
July 20, 2016
Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity
January 7, 2016
Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity
January 7, 2016
Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome
January 5, 2016
Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide
December 11, 2014
Rhythm Appoints Fred T. Fiedorek, M.D., Chief Medical Officer
June 23, 2014
Rhythm Presents Clinical Data that RM-493 Increases Energy Expenditure in Obesity Study
September 24, 2013
Rhythm Initiates Clinical Trial of RM-493 for Obesity Caused by Genetic Variant
January 4, 2013
Rhythm Initiates Phase 2 Clinical Trial of RM-493 for Obesity
  • First page «
  • Previous page ‹
  • …
  • Page 30
  • Page 31
  • Current page 32
  • Page 33
  • Next page ›
  • Last page »
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • California Compliance

Rhythm Pharmaceuticals, Inc.
222 Berkeley Street, 12th Floor
Boston, MA 02116

This website is intended only for residents of the United States.

© 2026, Rhythm Pharmaceuticals, Inc. All Rights Reserved. Rhythm, IMCIVREE, GOLD Academy, LEAD for Rare Obesity, Uncovering Rare Obesity, and their logos are trademarks of Rhythm Pharmaceuticals, Inc.

US-RHY-2400016 05/2024